ArticleMolecular and cellular biochemistry2026
The role of OLMALINC in small cell lung cancer progression and prognosis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OLMALINC has functions in several cancers; however, its function in small cell lung cancer (SCLC) cells and the possible regulatory mechanism are not well understood. Here, we identified the prognostic value of OLMALINC for SCLC and its role in SCLC progression. To identify the expression level of OLMALINC in SCLC, we performed quantitative real-time PCR (RT-PCR) assays in SCLC and adjacent tissue samples. To assess the prognostic potential of OLMALINC, Kaplan-Meier/log-rank tests, Multivariate Cox regression analyses, and time-dependent receiver operating characteristic curves were undertaken. To explore the cell function of OLMALINC in SCLC cells, OLMALINC was inhibited or overexpressed in vitro cell models, followed by apoptosis detection, invasion/migration tests, and determination of neuroendocrine markers (GRP and calcitonin). To identify the possible downstream targets, bioinformatics prediction, analyses of expression level correlation, RIP, RNA pull-down assays, and recovery experiments were conducted. A consistent upregulation of OLMALINC was observed in tumor tissues of SCLC patients and cell lines. OLMALINC upregulation was related to advanced AJCC or VALSG stage, poor overall survival, and poor recurrence-free survival. Gain/loss of function studies of OLMALINC in SCLC cell lines showed OLMALINC decreased cell apoptosis but increased cell migration/invasion and levels of GRP and calcitonin. OLMALINC interacted with SMARCA4, thus activating EZH2. OLMALINC modulated H3K27me3 of CCL2 to regulate CCL2 expression levels. OLMALINC can predict SCLC prognosis and promote SCLC progression.
Indexed as
Identifiers
42424008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.